Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck discontinues Phase III diabetes drug

Executive Summary

Merck hopes to file an NDA for antidiabetic DP-IV inhibitor in 2006 after terminating its Phase III MK-767 diabetes agent. Development of MK-767 was halted after long-term safety study identified a "rare form" of malignant tumors in mice, Merck says. MK-767 is the second Merck product to fail Phase III in as many weeks; the company recently terminated the substance P antagonist aprepitant (MK-0869) for depression (1"The Pink Sheet" Nov. 17, 2003, p. 34)...

You may also be interested in...



Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar

Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist

Merck Adds To Phase III Pipeline With Lundbeck Sleep-Aid Gaboxadol

Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent

Merck Drops Strict “No Merger” Policy, But Still Prefers Licensing Deals

Merck appears to be distancing itself from a blanket "no merger" policy by offering a formula under which it would consider a large-scale transaction

Related Content

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel